Peptide-based subunit nanovaccines

Current Drug Delivery

Volumn 8, Issue 3, 2011, Pages 282-289

  Skwarczynski, Mariusz ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Infectious diseases; Nanoparticles; Nanotechnology; Peptide epitope; Subunit vaccine

Indexed keywords

DRUG CARRIER; LIPID; NANOPARTICLE; NANOVACCINE; PEPTIDE DERIVATIVE; POLYMER; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; DRUG FORMULATION; HUMORAL IMMUNITY; NANOTECHNOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 79953804248     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111795256192     Document Type: Review

References (116)

1. Sahoo, S. K.; Parveen, S.; Panda, J. J. The present and future of nanotechnology in human health care. Nanomed. Nanotechnol. Biol. Med. 2007, 3 (1), 20-31.
2. Oppenheim, R. C. Solid Colloidal Drug Delivery Systems-Nanoparticles. Int. J. Pharm. 1981, 8 (3), 217-234.
3. Kreuter, J. Nanoparticle-based drug delivery systems. J. Control. Release 1991, 16 (1-2), 169-176.
4. Sandhiya, S.; Dkhar, S. A.; Surendiran, A. Emerging trends of nanomedicine-an overview. Fundam. Clin. Pharmacol. 2009, 23 (3), 263-269.
5. Medina, C.; Santos-Martinez, M. J.; Radomski, A.; Corrigan, O. I.; Radomski, M. W. Nanoparticles: pharmacological and toxicological significance. Br. J. Pharmacol. 2007, 150 (5), 552-558.
6. Pinto Reis, C.; Neufeld, R. J.; Ribeiro, A. J.; Veiga, F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomed. Nanotechnol. Biol. Med. 2006, 2, 53-65.
7. Singh, R.; Lillard, J. W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 2009, 86 (3), 215-223.
8. Nandedkar, T. D. Nanovaccines: recent developments in vaccination. J. Biosci. 2009, 34 (6), 995-1003.
9. Peek, L. J.; Middaugh, C. R.; Berkland, C. Nanotechnology in vaccine delivery. Adv. Drug Delivery Rev. 2008, 60 (8), 915-928.
10. Xiang, S. D.; Scholzen, A.; Minigo, G.; David, C.; Apostolopoulos, V.; Mottram, P. L.; Plebanski, M. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 2006, 40 (1), 1-9.
11. Purcell, A. W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. Nat. Rev. Drug Discov. 2007, 6 (5), 404-414.
12. Patarroyo, M. E.; Patarroyo, M. A. Emerging rules for subunitbased, multiantigenic, multistage chemically synthesized vaccines. Acc. Chem. Res. 2008, 41 (3), 377-386.
13. Tsuji, M.; Zavala, F. Peptide-based subunit vaccines against preerythrocytic stages of malaria parasites. Mol. Immunol. 2001, 38 (6), 433-442.
14. HogenEsch, H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 20, S34-S39.
15. Morein, B.; Hu, K. F.; Abusugra, I. Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Deliv. Rev. 2004, 56 (10), 1367-1382.
16. Scheerlinck, J. P. Y.; Greenwood, D. L. V. Virus-sized vaccine delivery systems. Drug Discov. Today 2008, 13 (19-20), 882-887.
17. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y. J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Release 2006, 116 (1), 1-27.
18. Chadwick, S.; Kriegel, C.; Amiji, M. Nanotechnology solutions for mucosal immunization. Adv. Drug Delivery Rev. 2010, 62, 394-407.
19. Sharma, S.; Mukkur, T. K. S.; Benson, H. A. E.; Chen, Y. Pharmaceutical Aspects of Intranasal Delivery of Vaccines Using Particulate Systems. J. Pharm. Sci. 2009, 98 (3), 812-843.
20. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 2009, 61 (2), 140-157.
21. Illum, L. Nanoparticulate systems for nasal delivery of drugs: A real improvement over simple systems? J. Pharm. Sci. 2007, 96 (3), 473-483.
22. Combadiere, B.; Mahe, B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis. 2008, 31 (2-3), 293-315.
23. Prausnitz, M. R.; Langer, R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26 (11), 1261-1268.
24. Lawson, L. B.; Freytag, L. C.; Clements, J. D. Use of nanocarriers for Transdermal vaccine delivery. Clin. Pharmacol. Ther. 2007, 82 (6), 641-643.
25. Batzloff, M. R.; Sriprakash, K. S.; Good, M. F. Vaccine development for group a streptococcus infections and associated diseases. Curr. Drug Targets 2004, 5 (1), 57-69.
26. Pruksakorn, S.; Currie, B.; Brandt, E.; Martin, D.; Galbraith, A.; Phornphutkul, C.; Hunsakunachai, S.; Manmontri, A.; Good, M. F. Toward a vaccine for rheumatic-fever-identification of a conserved target epitope on M-protein of group A streptococci. Lancet 1994, 344 (8923), 639-642.
27. Pruksakorn, S.; Currie, B.; Brandt, E.; Phornphutkul, C.; Hunsakunachai, S.; Manmontri, A.; Robinson, J. H.; Kehoe, M. A.; Galbraith, A.; Good, M. F. Identification of T-cell autoepitopes that cross-react with the C-terminal segment of the M-protein of group A streptococci Int. Immunol. 1994, 6 (8), 1235-1244.
28. Beck, A.; Klinguer-Hamour, C.; Bussat, M. C.; Champion, T.; Haeuw, J. F.; Goetsch, L.; Wurch, T.; Sugawara, M.; Milon, A.; Van Dorsselaer, A.; Nguyen, T.; Corvaia, N. Peptides as tools and drugs for immunotherapies. J. Pept. Sci. 2007, 13 (9), 588-602.
29. Sundaram, R.; Dakappagari, N. K.; Kaumaya, P. T. P. Synthetic peptides as cancer vaccines. Biopolymers 2002, 66 (3), 200-216.
30. Ertl, H. C. J.; Xiang, Z. Q. Novel vaccine approaches. J. Immunol. 1996, 156 (10), 3579-3582.
31. Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neill, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25 (10), 1159-1164.
32. Zhong, W.; Skwarczynski, M.; Toth, I. lipid core peptide system for gene, drug, and vaccine delivery. Aust. J. Chem. 2009, 62 (9), 956-967.
33. Chua, B. Y.; Zeng, W. G.; Lau, Y. F.; Jackson, D. C. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 2007, 25 (1), 92-101.
34. Moyle, P. M.; Toth, I. Self-adjuvanting lipopeptide vaccines. Curr. Med. Chem. 2008, 15 (5), 506-516.
35. Purcell, A. W.; Zeng, W. G.; Mifsud, N. A.; Ely, L. K.; MacDonald, W. A.; Jackson, D. C. Dissecting the role of peptides in the immune response: Theory, practice and the application to vaccine design. J. Pept. Sci. 2003, 9 (5), 255-281.
36. Zhong, W.; Skwarczynski, M.; Simerska, P.; Good, M. F.; Toth, I. Development of highly pure alpha-helical lipoglycopeptides as self-adjuvanting vaccines. Tetrahedron 2009, 65 (17), 3459-3464.
37. Zhong, W.; Skwarczynski, M.; Fujita, Y.; Simerska, P.; Good, M. F.; Toth, I. Design and synthesis of lipopeptide-carbohydrate assembled multivalent vaccine candidates using native chemical ligation. Aust. J. Chem. 2009, 62 (9), 993-999.
38. Zhong, W.; Skwarczynski, M.; I. T. Development of conformational mimetics of conserved streptococcus pyogenes minimal epitope as vaccine candidates. Curr. Drug Deliv. 2009, 6 (5), 520-527.
39. Boturyn, D.; Defrancq, E.; Dolphin, G. T.; Garcia, J.; Labbe, P.; Renaudet, O.; Dumy, P. RAFT nano-constructs: surfing to biological applications. J. Pept. Sci. 2008, 14 (2), 224-240.
40. Simerska, P.; Moyle, P. M.; Toth, I. Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products. Med. Res. Rev. 2010, in press.
41. Gentilucci, L.; Tolomelli, A.; Squassabia, F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr. Med. Chem. 2006, 13 (20), 2449-2466.
42. Adessi, C.; Soto, C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr. Med. Chem. 2002, 9 (9), 963-978.
43. Malik, D. K.; Baboota, S.; Ahuja, A.; Hasan, S.; Ali, J. Recent advances in protein and peptide drug delivery systems. Curr. Drug Deliv. 2007, 4 (2), 141-151.
44. Cox, J. C.; Coulter, A. R. Adjuvants-A classification and review of their modes of action. Vaccine 1997, 15 (3), 248-256.
45. Fifis, T.; Mottram, P.; Bogdanoska, V.; Hanley, J.; Plebanski, M. Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice. Vaccine 2004, 23 (2), 258-266.
46. Becerra, J. C.; Arthur, J. F.; Landucci, G. R.; Forthal, D. N.; Theuer, C. P. CD8+T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery 2003, 133 (4), 404-410.
47. Standley, S. M.; Kwon, Y. J.; Murthy, N.; Kunisawa, J.; Shastri, N.; Guillaudeu, S. J.; Lau, L.; Frechet, J. M. J. Acid-degradable particles for protein-based vaccines: Enhanced survival rate for tumor-challenged mice using ovalbumin model. Bioconjugate Chem. 2004, 15 (6), 1281-1288.
48. Watford, W. T.; Wang, C. C.; Tsatsanis, C.; Mielke, L. A.; Eliopoulos, A. G.; Daskalakis, C.; Charles, N.; Odom, S.; Rivera, J.; O'Shea, J.; Tsichlis, P. N. Ablation of tumor progression locus 2 promotes a type 2 th cell response in ovalbumin-immunized mice. J. Immunol. 2010, 184 (1), 105-113.
49. Fifis, T.; Gamvrellis, A.; Crimeen-Irwin, B.; Pietersz, G. A.; Li, J.; Mottram, P. L.; McKenzie, I. F. C.; Plebanski, M. Size-dependent immunogenicity: Therapeutic and protective properties of nanovaccines against tumors. J. Immunol. 2004, 173 (5), 3148-3154.
50. Mottram, P. L.; Leong, D.; Crimeen-Irwin, B.; Gloster, S.; Xiang, S. D.; Meanger, J.; Ghildyal, R.; Vardaxis, N.; Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 2007, 4 (1), 73-84.
51. Greenwood, D. L. V.; Dynon, K.; Kalkanidis, M.; Xiang, S.; Plebanski, M.; Scheerlinck, J. P. Y. Vaccination against foot-andmouth disease virus using peptides conjugated to nano-beads. Vaccine 2008, 26 (22), 2706-2713.
52. Reddy, S. T.; Rehor, A.; Schmoekel, H. G.; Hubbell, J. A.; Swartz, M. A. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 2006, 112 (1), 26-34.
53. Huang, H. Y.; Kowalewski, T.; Remsen, E. E.; Gertzmann, R.; Wooley, K. L. Hydrogel-coated glassy nanospheres: A novel method for the synthesis of shell cross-linked knedels. J. Am. Chem. Soc. 1997, 119 (48), 11653-11659.
54. Huang, H. Y.; Remsen, E. E.; Wooley, K. L. Amphiphilic coreshell nanospheres obtained by intramicellar shell crosslinking of polymer micelles with poly(ethylene oxide) linkers. Chem. Commun. 1998, (13), 1415-1416.
55. Becker, M. L.; Remsen, E. E.; Pan, D.; Wooley, K. L. Peptidederivatized shell-cross-linked nanoparticles. 1. Synthesis and characterization. Bioconjug. Chem. 2004, 15 (4), 699-709.
56. Becker, M. L.; Bailey, L. O.; Wooley, K. L. Peptide-derivatized shell-cross-linked nanoparticles. 2. Biocompatibility evaluation. Bioconjug. Chem. 2004, 15 (4), 710-717.
57. Mundargi, R. C.; Babu, V. R.; Rangaswamy, V.; Patel, P.; Aminabhavi, T. M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D, L-lactide-co-glycolide) and its derivatives. J. Control. Release 2008, 125 (3), 193-209.
58. Jiang, W. L.; Gupta, R. K.; Deshpande, M. C.; Schwendeman, S. P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 2005, 57 (3), 391-410.
59. Lutsiak, M. E. C.; Robinson, D. R.; Coester, C.; Kwon, G. S.; Samuel, J. Analysis of poly(D, L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 2002, 19 (10), 1480-1487.
60. Samuel, J.; Elamanchili, P.; Chong, C.; Lutsiak, C.; Newman, K.; Diwan, M.; Kwon, G. S. Biodegradable nanoparticles for targeted delivery of therapeutic vaccines to dendritic cells. FASEB J. 2003, 17 (7), C332-C332.
61. Elamanchili, P.; Diwan, M.; Cao, M.; Samuel, J. Characterization of poly(D, L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 2004, 22 (19), 2406-2412.
62. Elamanchili, P.; Lutsiak, C. M. E.; Hamdy, S.; Diwan, M.; Samuel, J. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells. J. Immunother. 2007, 30 (4), 378-395.
63. Lutsiak, M. E. C.; Kwon, G. S.; Samuel, J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J. Pharm. Pharmacol. 2006, 58 (6), 739-747.
64. Skwarczynski, M.; Hayashi, Y.; Kiso, Y. Paclitaxel prodrugs: Toward smarter delivery of anticancer agents. J. Med. Chem. 2006, 49 (25), 7253-7269.
65. Shih, I. L.; Van, Y. T.; Shen, M. H. Biomedical applications of chemically and microbiologically synthesized poly(glutamic acid) and poly(lysine). Mini-Rev. Med. Chem. 2004, 4 (2), 179-188.
66. Li, C. Poly(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 2002, 54 (5), 695-713.
67. Akagi, T.; Kaneko, T.; Kida, T.; Akashi, M. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with L-phenylalanine as a protein carrier. J. Control. Release 2005, 108 (2-3), 226-236.
68. Uto, T.; Wang, X.; Sato, K.; Haraguchi, M.; Akagi, T.; Akashi, M.; Baba, M. Targeting of antigen to dendritic cells with poly(gammaglutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J. Immunol. 2007, 178 (5), 2979-2986.
69. Uto, T.; Akagi, T.; Hamasaki, T.; Akashi, M.; Baba, M. Modulation of innate and adaptive immunity by biodegradable nanoparticles. Immunol. Lett. 2009, 125 (1), 46-52.
70. Matsuo, K.; Yoshikawa, T.; Oda, A.; Akagi, T.; Akashi, M.; Mukai, Y.; Yoshioka, Y.; Okada, N.; Nakagawa, S. Efficient generation of antigen-specific cellular immunity by vaccination with poly(gamma-glutamic acid) nanoparticles entrapping endoplasmic reticulum-targeted peptides. Biochem. Biophys. Res. Commun. 2007, 362 (4), 1069-1072.
71. Yamaguchi, S.; Tatsumi, T.; Takehara, T.; Sasakawa, A.; Yamamoto, M.; Kohga, K.; Miyagi, T.; Kanto, T.; Hiramastu, N.; Akagi, T.; Akashi, M.; Hayashi, N. EphA2-derived peptide vaccine with amphiphilic poly(gamma-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor. Cancer Immunol. Immunother. 2010, 59 (5), 759-767.
72. Akagi, T.; Baba, M.; Akashi, M. Preparation of nanoparticles by the self-organization of polymers consisting of hydrophobic and hydrophilic segments: Potential applications. Polymer 2007, 48 (23), 6729-6747.
73. Skwarczynski, M.; Zaman, M.; Urbani, C. N.; Lin, I. C.; Jia, Z. F.; Batzloff, M. R.; Good, M. F.; Monteiro, M. F.; Toth, I. Polyacrylate dendrimer nanoparticles: a self-adjuvanting vaccine delivery system. Angew. Chem. Int. Ed. 2010, 49 (33), 5742-5745.
74. Kakwere, H.; Chun, C. K. Y.; Jolliffe, K. A.; Payne, R. J.; Perrier, S. Polymer-peptide chimeras for the multivalent display of immunogenic peptides. Chem. Commun. 2010, 46 (13), 2188-2190.
75. Jung, J. P.; Nagaraj, A. K.; Fox, E. K.; Rudra, J. S.; Devgun, J. M.; Collier, J. H. Co-assembling peptides as defined matrices for endothelial cells. Biomaterials 2009, 30 (12), 2400-2410.
76. Malashkevich, V. N.; Kammerer, R. A.; Efimov, V. P.; Schulthess, T.; Engel, J. The crystal structure of a five-stranded coiled coil in COMP: A prototype ion channel? Science 1996, 274 (5288), 761-765.
77. Raman, S.; Machaidze, G.; Lustig, A.; Aebi, U.; Burkhard, P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomed.: Nanotechnol., Biol., Med. 2006, 2, 95-102.
78. Kaba, S. A.; Brando, C.; Guo, Q.; Mittelholzer, C.; Raman, S.; Tropel, D.; Aebi, U.; Burkhard, P.; Lanar, D. E. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol. 2009, 183 (11), 7268-7277.
79. Schroeder, U.; Graff, A.; Buchmeier, S.; Rigler, P.; Silvan, U.; Tropel, D.; Jockusch, B. M.; Aebi, U.; Burkhard, P.; Schoenenberger, C. A. peptide nanoparticles serve as a powerful platform for the immunogenic display of poorly antigenic actin determinants. J. Mol. Biol. 2009, 386 (5), 1368-1381.
80. Pimentel, T.; Yan, Z.; Jeffers, S. A.; Holmes, K. V.; Hodges, R. S.; Burkhard, P. peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 2009, 73 (1), 53-61.
81. Collier, J. H.; Messersmith, P. B. Enzymatic modification of selfassembled peptide structures with tissue transglutaminase. Bioconjugate Chem. 2003, 14 (4), 748-755.
82. Rudra, J. S.; Tian, Y. F.; Jung, J. P.; Collier, J. H. A selfassembling peptide acting as an immune adjuvant. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (2), 622-627.
83. Batzloff, M. R.; Hartas, J.; Zeng, W. G.; Jackson, D. C.; Good, M. F. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. J. Infect. Dis. 2006, 194 (3), 325-330.
84. Zaman, M.; Abdel-Aal, A. M.; Phillipps, K. S. M.; Fujita, Y.; Good, M. F.; Toth, I. Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2. Vaccine 2010, 28 (10), 2243-2248.
85. Uemura, A.; Watarai, S.; Iwasaki, T.; Kodama, H. Induction of immune responses against glycosphingolipid antigens: Comparison of antibody responses in mice immunized with antigen associated with liposomes prepared from various phospholipids. J. Vet. Med. Sci. 2005, 67 (12), 1197-1201.
86. Phillipps, K. S. M.; Wykes, M. N.; Liu, X. Q.; Brown, M.; Blanchfield, J.; Toth, I. A novel synthetic adjuvant enhances dendritic cell function. Immunology 2009, 128 (1), e582-e588.
87. Yan, W.; Huang, L. Recent advances in liposome-based nanoparticles for antigen delivery. Polym. Rev. 2007, 47 (3), 329-344.
88. Cui, Z. R.; Han, S. J.; Vangasseri, D. P.; Huang, L. Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol. Pharm. 2005, 2 (1), 22-28.
89. Irache, J. M.; Salman, H. H.; Gamazo, C.; Espuelas, S. Mannosetargeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 2008, 5 (6), 703-724.
90. Cui, Z. G.; Han, S. J.; Huang, L. Coating of mannan on LPD particles containing HPV E7 peptide significantly enhances immunity against HPV-positive tumor. Pharm. Res. 2004, 21 (6), 1018-1025.
91. Boato, F.; Thomas, R. M.; Ghasparian, A.; Freund-Renard, A.; Moehle, K.; Robinson, J. A. Synthetic virus-like particles from self-assembling coiled-coil lipopeptides and their use in antigen display to the immune system. Angew. Chem. Int. Ed. 2007, 46 (47), 9015-9018.
92. Bhattacharya, R.; Mukherjee, P. Biological properties of "naked" metal nanoparticles. Adv. Drug Deliv. Rev. 2008, 60 (11), 1289-1306.
93. Murakami, T.; Tsuchida, K. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini-Rev. Med. Chem. 2008, 8 (2), 175-183.
94. Nair, L. S.; Laurencin, C. T. Silver nanoparticles: Synthesis and therapeutic applications. J. Biomed. Nanotechnol. 2007, 3 (4), 301-316.
95. Son, S. J.; Bai, X.; Lee, S. B. Inorganic hollow nanoparticles and nanotubes in nanomedicine. Part 1. Drug/gene delivery applications. Drug Discov. Today 2007, 12 (15-16), 650-656.
96. Xu, Z. P.; Zeng, Q. H.; Lu, G. Q.; Yu, A. B. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem. Eng. Sci. 2006, 61 (3), 1027-1040.
97. Frey, A.; Neutra, M. R.; Robey, F. A. Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: Synthesis and characterization of a conjugate derived from the C4 domain of HIV-1(MN) gp120. Bioconjug. Chem. 1997, 8 (3), 424-433.
98. Frey, A.; Mantis, N.; Kozlowski, P. A.; Quayle, A. J.; Bajardi, A.; Perdomo, J. J.; Robey, F. A.; Neutra, M. R. Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. Vaccine 1999, 17 (23-24), 3007-3019.
99. Foldvari, M.; Bagonluri, M. Carbon nanotubes as functional excipients for nanomedicines: I. pharmaceutical properties. Nanomed. Nanotechnol. Biol. Med. 2008, 4 (3), 173-182.
100. Foldvari, M.; Bagonluri, M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomed. Nanotechnol. Biol. Med. 2008, 4 (3), 183-200.
101. Prato, M.; Kostarelos, K.; Bianco, A. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res. 2008, 41 (1), 60-68.
102. Pagona, G.; Tagmatarchis, N. Carbon nanotubes: Materials for medicinal chemistry and biotechnological applications. Curr. Med. Chem. 2006, 13 (15), 1789-1798.
103. Pantarotto, D.; Partidos, C. D.; Graff, R.; Hoebeke, J.; Briand, J. P.; Prato, M.; Bianco, A. Synthesis, structural characterization, and immunological properties of carbon nanotubes functionalized with peptides. J. Am. Chem. Soc. 2003, 125 (20), 6160-6164.
104. Pantarotto, D.; Partidos, C. D.; Hoebeke, J.; Brown, F.; Kramer, E.; Briand, J. P.; Muller, S.; Prato, M.; Bianco, A. Immunization with peptide-functionalized carbon nanotubes enhances virus-specific neutralizing antibody responses. Chem. Biol. 2003, 10 (10), 961-966.
105. Yandara, N.; Pastorin, G.; Prato, M.; Bianco, A.; Patarroyo, M. E.; Lozano, J. M. Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model. Vaccine 2008, 26 (46), 5864-5873.
106. Kagan, V. E.; Konduru, N. V.; Feng, W.; Allen, B. L.; Conroy, J.; Volkov, Y.; Vlasova, I. I.; Belikova, N. A.; Yanamala, N.; Kapralov, A.; Tyurina, Y. Y.; Shi, J.; Kisin, E. R.; Murray, A. R.; Franks, J.; Stolz, D.; Gou, P.; Klein-Seetharaman, J.; Fadeel, B.; Star, A.; Shvedova, A. A. Carbon nanotubes degraded by neutrophil myeloperoxidase induce less pulmonary inflammation. Nat. Nanotechnol. 2010, 5 (5), 354-359.
107. Reddy, S. T.; Berk, D. A.; Jain, R. K.; Swartz, M. A. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol. 2006, 101 (4), 1162-1169.
108. Oussoren, C.; Storm, G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 2001, 50 (1-2), 143-156.
109. Nishioka, Y.; Yoshino, H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 2001, 47 (1), 55-64.
110. Reddy, S. T.; Swartz, M. A.; Hubbell, J. A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006, 27 (12), 573-579.
111. Seong, S. Y.; Matzinger, P. Hydrophobicity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4 (6), 469-478.
112. Hunter, R.; Strickland, F.; Kezdy, F. The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophilelipophile balance. J. Immunol. 1981, 127 (3), 1244-1250.
113. Hilgers, L. A. T.; Ghenne, L.; Nicolas, I.; Fochesato, M.; Lejeune, G.; Boon, B. Alkyl-polyacrylate esters are strong mucosal adjuvants. Vaccine 2000, 18 (28), 3319-3325.
114. O'Hagan, D.; Singh, M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2003, 2 (2), 269-283.
115. Garnett, M. C.; Kallinteri, P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. 2006, 56 (5), 307-311.
116. Kabanov, A. V. Polymer genomics: An insight into pharmacology and toxicology of nanomedicines. Adv. Drug Deliv. Rev. 2006, 58 (15), 1597-1621.